AlphAIAlphAI — Financial news for AI agents
stocktitan.net$PHIO

Study results suggest a skin cancer treatment may spare tissue before surgery

Phio Pharmaceuticals (PHIO) announced positive Phase 1b trial results for its skin cancer treatment PH-762, to be presented at the SITC meeting. The data suggests PH-762 may shrink tumors before surgery with a favorable safety profile, according to the company. A Phase 2b study is planned for 2027.

Original reporting
stocktitan.net
Published Nov 6, 2026, 2:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PHIO
Bullish
high confidence
Mentioned
$PHIO
Relevance
9/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PHIOBullishMed
01

Why it matters

The announcement provides the first public efficacy and safety readout for PH‑762, a neoadjuvant treatment that could reduce surgical burden.

02

Market read

Early positive trial data can trigger short‑term price moves in PHIO and influence sentiment toward RNA‑based oncology assets.

03

What to watch

Potential regulatory hurdles and need for larger Phase 2b data could temper enthusiasm.

Relevance 9/10Novelty 9/10Timing: today

Background

Phio Pharmaceuticals is a clinical‑stage company developing siRNA therapeutics; the INTASYL platform targets PD‑1 in skin cancers.

Company-level read

Ticker impact

$PHIOBullishHigh confidence
Context

Phio Pharmaceuticals announced Phase 1b trial results for its INTASYL PH-762 skin‑cancer therapy, showing safety and potential tissue‑sparing efficacy.

Expected impact

likely upward pressure as market prices in favorable trial outcomes

Evidence & confidence

First disclosure of Phase 1b results for a novel siRNA cancer therapy; biotech stocks typically react strongly to early clinical data.

Market effects

Sector

Strengthens the siRNA oncology segment and may lift peer biotech stocks developing similar therapies.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Adds to global interest in RNA‑based cancer treatments.

Counterpoint

What could challenge this read

Phase 1b data are early; efficacy still unproven and future trials may not confirm benefits.

Key entities

  • company
    Phio Pharmaceuticals Corp.

    NASDAQ‑listed biotech developing INTASYL siRNA therapies.

  • executive
    Robert Bitterman

    President and CEO of Phio, quoted on trial results.

Read at source← All news

StoryPhio to present Phase 1b skin‑cancer trial data at SITC meeting

Also covered by

1 outlet

Related articles

$PHIOMedAI 8/10

Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

Phio Pharmaceuticals (PHIO) presented Phase 1b trial data for its cancer treatment PH-762 at the ASDS Annual Meeting. The study suggested PH-762 is well-tolerated and may offer a tissue-sparing neoadjuvant therapy for cutaneous carcinomas. A Phase 2b study is planned for 2027. According to the company, PH-762 could improve patient outcomes by shrinking tumors before surgery.

timminspress.com
$PHIOMedAI 8/10

Phio Pharmaceuticals 3Q 2026: EPS ($0.36) — 10-Q Summary

Phio Pharmaceuticals reported a wider net loss of $4.16M in 3Q 2026, up 73.9% YoY, due to increased R&D and regulatory costs. EPS was ($0.36). The company advanced PH-762 toward a Phase 2b study, with a 65% response rate in Phase 1b trials. Manufacturing of PH-762 drug substance began in 3Q 2026.

tradingview.com
$PHIOMed

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatmen

SEC EDGAR 8-K
$PHIOMedAI 8/10

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation

Phio Pharmaceuticals (PHIO) reported Q3 2026 results, advancing PH-762 toward Phase 2b study. Key milestones include FDA submission, commercial-scale manufacturing, and patent achievements. The company expects FDA feedback by November 2026 and Phase 2b initiation in Q1 2027. Financial details include cash position, R&D, and G&A expenses, with net loss reported.

stocktitan.net